EHA 2024: Updates in the Treatment of CLL : Episode 6
Opinion
Video
Dr Danilov Reviews EHA 2024 Data on the Role of 1L Triplet Therapy in CLL
Author(s):
Experts analyze the potential applications of triplet therapy (venetoclax, BTK inhibitor, and obinutuzumab) in first-line chronic lymphocytic leukemia treatment, focusing on patient subgroups most likely to benefit from this approach.
EP: 1.Introducing the Expert Panel on CLL Treatment Updates Live at EHA 2024
EP: 2.Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL
EP: 3.Frontline BTKi Selection
EP: 4.Dr Parrondo’s Frontline CLL Treatment Approach for Pre-existing HTN and Afib
EP: 5.Dr Lamanna Reviews Study Data for 1L Doublet Therapy or Triplet Therapy
Now Viewing
EP: 6.Dr Danilov Reviews EHA 2024 Data on the Role of 1L Triplet Therapy in CLL
EP: 7.EHA 2024 Review of Ongoing Trials Evaluating BCL2i/BTKi Combination Approaches
EP: 8.Navigating Treatment Approaches for R/R CLL
EP: 9.How Experts View MAIC Data That was Presented at EHA 2024
EP: 10.BTKi Intolerance in Real-world Practice & Management Strategy
EP: 11.Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities
EP: 12.Approach to Hypertension Management With BTKi Treatment
EP: 13.Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib
EP: 14.Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing
EP: 15.Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice
EP: 16.TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices
EP: 17.EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL
EP: 18.Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673
EP: 19.Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL
EP: 20.Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies
EP: 21.Clinical Pearls and Impacts to Practice from EHA 2024
- What is the potential role of triplet therapy (VEN + BTKI + OBI) in the 1L treatment of CLL? In which patients may this strategy be most appropriate?
Related Videos
Related Content
